메뉴 건너뛰기
New England Journal of Medicine
Volumn 348, Issue 2, 2003, Pages 177-178
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus [6]
Author keywords

[No Author keywords available]
Indexed keywords

DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA;
EID: 0037426728     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200301093480218     Document Type: Letter
Times cited : (146)
References (4)
  • 1
    • 0032760120 scopus 로고    scopus 로고
    • Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    • Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
    • (1999) Hepatology , vol.30 , pp. 1302-1306
    • Benhamou, Y.1    Bochet, M.2    Thibault, V.3
  • 2
    • 0035449134 scopus 로고    scopus 로고
    • Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study
    • Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001; 358:718-23.
    • (2001) Lancet , vol.358 , pp. 718-723
    • Benhamou, Y.1    Bochet, M.2    Thibault, V.3
  • 3
    • 0034108712 scopus 로고    scopus 로고
    • Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
    • Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-5.
    • (2000) J Viral Hepat , vol.7 , pp. 161-165
    • Ying, C.1    De Clercq, E.2    Nicholson, W.3    Furman, P.4    Neyts, J.5
  • 4
    • 0003300455 scopus 로고    scopus 로고
    • Tenofovir DF: A 48-week final analysis from a phase III, randomized, double-blind, placebo-controlled study in antiretroviral-experienced patients (study 907)
    • Seattle, February 24-28, abstract
    • Squires K, Pierone G, Berger D, et al. Tenofovir DF: A 48-week final analysis from a phase III, randomized, double-blind, placebo-controlled study in antiretroviral-experienced patients (study 907). In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002. abstract.
    • (2002) Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections
    • Squires, K.1    Pierone, G.2    Berger, D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.